Kala Bio (KALA) Other Non Operating Income (2021 - 2026)
Kala Bio (KALA) posted Other Non Operating Income of $107000.0 for Q1 2026, down 98.19% sequentially from $5.9 million in Q4 2025, and down 95.45% YoY from $2.3 million in Q1 2025.
Kala Bio (KALA) Other Non Operating Income (2021 - 2026) Analysis & Trends
Kala Bio has reported Other Non Operating Income for 6 years, with the latest figure at $107000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 95.45% year-over-year to $107000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (down 13.74% YoY) and the FY2025 annual result came in at $5.8 million, down 6.55% from the prior year.
- Other Non Operating Income eased to $107000.0 in Q1 2026 per KALA's latest filing, from $5.9 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $5.9 million in Q4 2025 and troughed at -$3.0 million in Q4 2022.
- A 5-year average of $341933.3 and a median of $107000.0 in 2026 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income soared 44060.0% in 2024, then plunged 105.76% in 2025.
- Over 5 years, Other Non Operating Income stood at -$3.0 million in 2022, then soared by 99.83% to -$5000.0 in 2023, then jumped by 44060.0% to $2.2 million in 2024, then soared by 168.65% to $5.9 million in 2025, then slumped by 98.19% to $107000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $107000.0, $5.9 million, and -$112000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 107,000.00 |
| Dec 31, 2025 | 5.91 Mn |
| Sep 30, 2025 | -112,000.00 |
| Jun 30, 2025 | 547,000.00 |
| Mar 31, 2025 | 2.35 Mn |
| Dec 31, 2024 | 2.20 Mn |
| Sep 30, 2024 | 1.95 Mn |
| Jun 30, 2024 | 980,000.00 |
| Mar 31, 2024 | 1.08 Mn |
| Dec 31, 2023 | -5,000.00 |
| Sep 30, 2023 | -2.16 Mn |
| Jun 30, 2023 | -119,000.00 |
| Mar 31, 2023 | -1.97 Mn |
| Dec 31, 2022 | -3.03 Mn |
| Sep 30, 2022 | -2.58 Mn |
| Jun 30, 2021 | -5.40 Mn |